And then the fact the phase 2a produced results in the 200mg arm of achieving the primary endpoint of showing a GREATER THAN OR EQUAL TO a 2 point reduction using the IGA scale in 35% of patients.
And the percentage was greater if you filtered only MODERATE (IGA 3) patients. I think it was 46% or something. Moving from 3 to 1 or 0 is considered higher than a PASI 75. And the trial proved a dose dependency. So I'm expecting 300 and 400 to show even better data.